Clinical Trial Update: A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

A Phase 2 multicenter randomized open-label trial evaluating MEDI-551 (milatuzumab) in adults with relapsed or refractory diffuse large B-cell lymphoma; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• MEDI-551 (inebilizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-03-12